{
  "task_name": "toxcast",
  "task_description": "Compound with activity in ToxCast assays indicating potential toxicity",
  "subtasks": {
    "APR_HepG2_MitoMass_24h_dn": {
      "description": "Decrease in mitochondrial mass in HepG2 cells after 24 hours exposure",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound decreases mitochondrial mass in HepG2 cells after 24 hours of exposure. Please modify its structure to reduce its impact on mitochondrial function while maintaining its primary therapeutic activity. Consider structural features that might disrupt mitochondrial biogenesis or promote mitochondrial degradation."
    },
    "BSK_3C_ICAM1_down": {
      "description": "Downregulation of ICAM1 expression in the BioMAP 3C system",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound downregulates ICAM1 expression in the BioMAP 3C system. Please modify its structure to reduce its impact on this important cell adhesion molecule while maintaining its intended therapeutic effect. Focus on reducing structural features that may interfere with inflammatory and immune signaling pathways."
    },
    "Tanguay_ZF_120hpf_TR_up": {
      "description": "Increased trunk response in zebrafish at 120 hours post-fertilization",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound increases the trunk response in zebrafish at 120 hours post-fertilization. Please modify its structure to reduce this developmental/neurobehavioral toxicity while maintaining its therapeutic properties. Consider structural modifications that may reduce neurotoxicity or developmental effects."
    },
    "ATG_M_32_CIS_dn": {
      "description": "Downregulation of CIS element activity in the Attagene transcription factor assay",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound downregulates CIS element activity in the Attagene transcription factor assay. Please modify its structure to reduce this transcriptional effect while preserving its primary pharmacological activity. Focus on features that may interact with transcription factors or alter gene expression."
    },
    "ATG_RORg_TRANS_up": {
      "description": "Upregulation of RORγ transcriptional activity",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound upregulates RORγ transcriptional activity. Please modify its structure to reduce its impact on this nuclear receptor while maintaining its therapeutic efficacy. Consider structural elements that may interact with nuclear receptors or affect their signaling."
    },
    "TOX21_p53_BLA_p3_ch2": {
      "description": "Activation of the p53 pathway in the Tox21 β-lactamase reporter gene assay",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound activates the p53 pathway in the Tox21 β-lactamase reporter gene assay. Please modify its structure to reduce p53 activation while preserving its intended therapeutic action. Focus on reducing features that may cause DNA damage or cellular stress leading to p53 activation."
    },
    "BSK_3C_MCP1_down": {
      "description": "Downregulation of MCP1 (CCL2) in the BioMAP 3C system",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound downregulates MCP1 (CCL2) in the BioMAP 3C system. Please modify its structure to normalize MCP1 expression while maintaining its therapeutic activity. Consider structural features that may interfere with chemokine signaling or inflammatory pathways."
    },
    "ATG_MRE_CIS_up": {
      "description": "Upregulation of metal response element activity in the Attagene CIS assay",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound upregulates metal response element activity in the Attagene CIS assay. Please modify its structure to reduce this effect while preserving its primary therapeutic function. Focus on structural features that may chelate metals or disrupt metal homeostasis pathways."
    },
    "NVS_GPCR_gLTB4": {
      "description": "Interaction with the leukotriene B4 receptor in the Novascreen GPCR assay",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound interacts with the leukotriene B4 receptor in the Novascreen GPCR assay. Please modify its structure to reduce binding to this inflammatory mediator receptor while maintaining its therapeutic properties. Consider structural elements that may mimic the LTB4 ligand or interact with this GPCR."
    },
    "NVS_ENZ_hAChE": {
      "description": "Inhibition of human acetylcholinesterase in the Novascreen enzyme assay",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound inhibits human acetylcholinesterase in the Novascreen enzyme assay. Please modify its structure to reduce AChE inhibition while preserving its primary pharmacological activity. Focus on features that may interact with the AChE active site or binding pocket."
    },
    "default": {
      "description": "General ToxCast-identified toxicity",
      "instruction": "Given molecule with the provided SMILES and molecular structure image, this compound has shown activity in ToxCast assays indicating potential toxicity. Please modify its structure to reduce this toxic effect while maintaining its therapeutic properties. Consider general strategies for reducing toxicity such as decreasing reactivity, improving specificity, or altering physicochemical properties."
    }
  },
  "focus_points": [
    "Modify structural features that may interact with the specific molecular targets identified",
    "Reduce reactive functional groups that could form adducts with proteins or DNA",
    "Alter the compound's physicochemical properties to reduce distribution to sensitive tissues",
    "Consider the role of metabolism in activating or deactivating the compound",
    "Maintain structural features essential for the compound's intended therapeutic target while modifying toxicity-related elements"
  ],
  "output_format": "Please propose specific structural modifications to address the identified toxicity mechanism while preserving the molecule's intended pharmacological properties."
} 